Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review


  • Eva M Gamper
  • Jammbe Z Musoro
  • Corneel Coens
  • Jean-Jacques Stelmes
  • Claudette Falato
  • Mogens Groenvold
  • Galina Velikova
  • Kim Cocks
  • Hans-Henning Flechtner
  • Madeleine T King
  • Andrew Bottomley
  • EORTC Genito-Urinary Tract Cancer Group and Quality of Life Groups
Vis graf over relationer

BACKGROUND: The aim of the study was to estimate the minimally important difference (MID) for interpreting group-level change over time, both within a group and between groups, for the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) scores in patients with prostate cancer.

METHODS: We used data from two published EORTC trials. Clinical anchors were selected by strength of correlations with QLQ-C30 scales. In addition, clinicians' input was obtained with regard to plausibility of the selected anchors. The mean change method was applied for interpreting change over time within a group of patients and linear regression models were fitted to estimate MIDs for between-group differences in change over time. Distribution-based estimates were also evaluated.

RESULTS: Two clinical anchors were eligible for MID estimation; performance status and the CTCAE diarrhoea domain. MIDs were developed for 7 scales (physical functioning, role functioning, social functioning, pain, fatigue, global quality of life, diarrhoea) and varied by scale and direction (improvement vs deterioration). Within-group MIDs ranged from 4 to 14 points for improvement and - 13 to - 5 points for deterioration and MIDs for between-group differences in change scores ranged from 3 to 13 for improvement and - 10 to - 5 for deterioration.

CONCLUSIONS: Our findings aid the meaningful interpretation of changes on a set of EORTC QLQ-C30 scale scores over time, both within and between groups, and for performing more accurate sample size calculations for clinical trials in prostate cancer.

TidsskriftBMC Cancer
Udgave nummer1
Sider (fra-til)1083
Antal sider8
StatusUdgivet - dec. 2021

Bibliografisk note

© 2021. The Author(s).

ID: 69265103